Santhera Raises CHF45m Ahead Of Duchenne Drug Filing
Vamorolone Submission Planned For Q1 Next Year
A mix of equity and debt financing has raised enough to satisfy Santhera's liquidity needs until mid-2022, which will be after the Swiss firm has filed its Duchenne drug vamorolone.
